GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Lixisenatide (AVE0010)

Self administered by subcutaneous injections once daily within the hour preceding breakfast.

DEVICE

Pen auto-injector

Trial Locations (1)

Sanofi-Aventis Administrative Office, Tokyo